Results 51 to 60 of about 115,437 (312)

Advances in tumor-infiltrating B lymphocytes

Central European Journal of Immunology
In the landscape of tumor immunotherapy, T cell-mediated immune responses have consistently captured the attention, while the contributions of B cells have been neglected.
Yule Zhang, Ming Huang, Jinxiu Chen, Chunyu Cao, Hongyan Wu   +4 more
doaj   +1 more source

Protocol for Single-Cell Analysis of Tumor-Infiltrating B Cells Isolated from Human Breast Cancer Tissue Before and After Neo-adjuvant Chemotherapy

STAR Protocols, 2020
SUMMARY: Single-cell analysis of tumor-infiltrating lymphocytes obtained before and after preoperative therapy reflects the dynamic interplay of the tumor and immune system during treatment.
Yiwen Lu, Jian-You Liao, Shicheng Su
doaj   +1 more source

Combining antibody conjugates with cytotoxic and immune‐stimulating payloads maximizes anti‐cancer activity

Molecular Oncology, EarlyView.
Methods to improve antibody–drug conjugate (ADC) treatment durability in cancer therapy are needed. We utilized ADCs and immune‐stimulating antibody conjugates (ISACs), which are made from two non‐competitive antibodies, to enhance the entry of toxic payloads into cancer cells and deliver immunostimulatory agents into immune cells.
Tiexin Wang, Dong Jun Koo, Peter M. Tessier, Greg M. Thurber   +3 more
wiley   +1 more source

Isolation of TCR genes with tumor-killing activity from tumor-infiltrating and circulating lymphocytes in a tumor rejection cynomolgus macaque model [PDF]

, 2021
Koji Terada, Kenta Kondo, Hirohito Ishigaki, Ayaka Nagashima, Hiroki Satooka, Seiji Nagano, Kyoko Masuda, Teruhisa Kawamura, Takako Hirata, Kazumasa Ogasawara, Yasushi Itoh, Hiroshi Kawamoto, Yasutoshi Agata   +12 more
openalex   +1 more source

The PI3Kδ inhibitor roginolisib (IOA‐244) preserves T‐cell function and activity

Molecular Oncology, EarlyView.
Identification of novel PI3K inhibitors with limited immune‐related adverse effects is highly sought after. We found that roginolisib and idelalisib inhibit chronic lymphocytic leukemia (CLL) cells and Treg suppressive functions to similar extents, but roginolisib affects cytotoxic T‐cell function and promotion of pro‐inflammatory T helper subsets to a
Elise Solli, Alessio Bevilacqua, Mathias Wenes, Denis Migliorini, Lars van der Veen, Sigrid S Skånland, Giusy Di Conza, Kjetil Taskén   +7 more
wiley   +1 more source

Intratumoral immune cells expressing PD-1/PD-L1 and their prognostic implications in cancer: a meta-analysis

The International Journal of Biological Markers, 2018
Background: The prognostic value of immune cells expressing programmed cell death 1 (PD-1) and PD-1 ligand 1 (PD-L1) in cancer are controversial, and the potential differential impact of using tissue microarrays and whole tissue sections to assess the ...
Younghoon Kim, Xianyu Wen, Nam Yun Cho, Gyeong Hoon Kang   +3 more
doaj   +1 more source

Adoptive tumor infiltrating lymphocytes cell therapy for cervical cancer

Human Vaccines & Immunotherapeutics, 2022
Cervical cancer is one of the most common malignancies among females. As a virus-related cancer, cervical cancer has attracted a lot of attention to develop virus-targeted immune therapy, including vaccine and adoptive immune cell therapy (ACT). Adoptive
Yahui Zhu, Jing Zhou, Lijing Zhu, Wenjing Hu, Baorui Liu, Li Xie   +5 more
doaj   +1 more source

P8‐59: Drebrin‐positive tumor‐infiltrating lymphocytes as a prognostic biomarker for lung squamus cell carcinoma [PDF]

, 2021
S. Sakamoto, Kazuhiro Sato, Satoshi Goshima, Ruriko Asahi, Yuri Takita, Eiki Omoto, Yuka Izumiya, Naho Kumagai, Yukiyasu Hasegawa, Hayato Yokota, Yūji Okuda, Mariko Asano, Yumiko Akamine, Masahide Takeda, Masatomo Miura, Kastutoshi Nakayama, Kosuke Imamura, Yusuke Tomita, Ryo Sato, Tokunori Ikeda, Shinji Iyama, Yoshihiko Goto, Moriyasu Anai, Takayuki Jodai, Shinya Sakata, Koichi Saruwatari, Sho Saeki, Koei Ikeda, Makoto Suzuki, Takuro Sakagami   +29 more
openalex   +1 more source

Cotargeting TREM2 and IL2 pathways triggers multipronged anticancer immunity

Molecular Oncology, EarlyView.
Von Locquenghien et al. report that MiTE‐144, a triggering receptor expressed on myeloid cells 2 (TREM2) blocking antibody fused to interleukin‐2 (IL2) variant with tumour microenvironment restricted activation, demonstrates superior anticancer efficiency in a preclinical setting.
Isaure Vanmeerbeek, Jenny Sprooten, Abhishek D. Garg   +2 more
wiley   +1 more source

The role of tumor-infiltrating lymphocytes in cholangiocarcinoma

Journal of Experimental & Clinical Cancer Research, 2022
Cholangiocarcinoma (CCA) is the second most common primary liver cancer and associated with a dismal prognosis due to the lack of an efficient systemic therapy. In contrast to other cancers, new immunotherapies have demonstrated unsatisfactory results in
Dong Liu, Lara Rosaline Heij, Zoltan Czigany, Edgar Dahl, Sven Arke Lang, Tom Florian Ulmer, Tom Luedde, Ulf Peter Neumann, Jan Bednarsch   +8 more
doaj   +1 more source